Who is sponsoring NCT03166527?

NCT03166527 is sponsored by Vera Bril.

What drugs are being tested in NCT03166527?

Interventions in NCT03166527: Immune Globulin 10% Intravenous Solution.

What condition does NCT03166527 study?

NCT03166527 studies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Is NCT03166527 still recruiting?

NCT03166527 is currently status unknown. Last updated 25 May 2017.

Last reviewed 2017-05-25 · How we verify

NCT03166527: Panzyga-CIDP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Panzyga in CIDP Administered at Different Infusion Rates

Status unknown Phase 3 Last updated 25 May 2017

What this trial tests

Phase 3 trial testing Immune Globulin 10% Intravenous Solution in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 30 participants. Status unknown.

Timeline

1 June 2017

Primary endpoint
15 December 2018

15 December 2018

Quick facts

Lead sponsor	Vera Bril
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 June 2017
Primary completion	15 December 2018
Estimated completion	15 December 2018
Sites	1 location across Canada

Drugs / interventions tested

Immune Globulin 10% Intravenous Solution — full drug profile →

Conditions studied

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — all drugs for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) →

Sponsor

Vera Bril — full company profile →

Who can join

18 and older, any sex, with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit, taking up resources such as nursing time and hospital space. Chronic treatment is required in most cases.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
Briani C, Visentin A. · · 2022 · cited 39× · PMID 35349079 · DOI 10.1007/s13311-022-01222-x

Verify or expand the search:

Other recruiting trials for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Currently open trials in the same condition.

NCT07526493 — Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media · Phase 1 · recruiting
NCT07337785 — CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT06040567 — Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study · recruiting
NCT04280718 — A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03166527 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vera Bril
Last refreshed: 25 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03166527.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing